Abstract 155P
Background
Circulating tumor cells (CTCs) are cells of epithelial origin from clones of the primary tumor, located in the G0 phase and found in the peripheral blood of patients with various forms of solid cancer. Currently, CTCs are found in breast cancer, prostate cancer, colorectal cancer, and their number is used as an independent prognostic factor. The detection of CTCs in various tumors can help in the study of the process of metastasis and the biology of tumor growth. The aim of the work is to establish the presence and frequency of CTCs in the peripheral blood of patients with cancer in the bladder.
Methods
41 peripheral blood samples from patients with verified bladder cancer of stage III-IV were analyzed. The blood was taken into vacuum tubes with anticoagulant. The selection of the CTC on the density gradient. From the obtained material, 2 cytological preparations were prepared on the cytocentrifuge of Hospitex diagnostics (Italy) and stained according to Romanovsky. Calculation of the CTC at the light-optical level using a Zeiss Primo Star microscope (Germany). The final result was the total number of detected CTCs. The control group consisted of peripheral blood samples from 10 patients without cancer.
Results
CTCs were detected in 46.3% of cases (19 samples) in the amount of 1-14 cells. In the morphological structure of primary tumors, according to the results of histological examination, the samples were divided as follows: squamous cell carcinoma – 1, adenocarcinoma (metastasis of cervical cancer) – 1, urothelial carcinoma – 17. The calculation of the CTC by morphological forms of the tumor showed that 4-6 cells were detected in squamous cell carcinoma, 6 cells in adenocarcinoma, and 2 - 14 cells in urothelial carcinoma (2-4 cells in the II st., 7-14 cells in the IIII st.; Xsr=2.43). In the blood samples of the control patients, CTCs were also not detected.
Conclusions
The presence of CTC in the peripheral blood of patients with bladder cancer was detected in 46.3% of cases and has differences depending on the morphological form of the tumor, which requires further study. The largest number of CTCs in our study was revealed in the transitional cell (urothelial) morphological form of cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
167P - Genetic testing for prostate cancer: The Indian scenario
Presenter: Ganesh Bakshi
Session: Poster viewing 03
168P - Transcriptional profiling of metastatic hormone sensitive prostate cancer (mHSPC) and distinct features are associated with clinical outcome
Presenter: BYULA JEE
Session: Poster viewing 03
169P - Urine tumor DNA fragmentation profiles provided a novel biomarker for early detection of prostate cancer
Presenter: Nianzeng Xing
Session: Poster viewing 03
170P - Safety, efficacy and pharmacoeconomic implications of low dose abiraterone in prostate cancer
Presenter: Suryakanta Acharya
Session: Poster viewing 03
171P - Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy
Presenter: Jin Cho
Session: Poster viewing 03
172P - Impact on management of non-metastatic prostate cancer biochemical recurrence with use of 68Ga PET-PSMA PET/CT scans in single-institution experience
Presenter: Pimchanok Tuitemwong
Session: Poster viewing 03
173P - Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Francis Parnis
Session: Poster viewing 03
175TiP - A prospective phase II study to investigate the efficacy and safety of olaparib plus abiraterone and prednisone combination therapy in mHSPC patients with HRR gene mutation
Presenter: Junlong Zhuang
Session: Poster viewing 03
186P - Degradation of BRCA2 expression by hyperthermia sensitizes HRD-negative (BRCA2 wild-type) ovarian cancer cells to niraparib
Presenter: Junyang Li
Session: Poster viewing 03